Impact of Natalizumab on Cognitive Performances and Fatigue in Relapsing Multiple Sclerosis: A Prospective, Open-Label, Two Years Observational Study

Multiple Sclerosis-Associated Fatigue during Disease-Modifying Treatment with Natalizumab, Interferon-Beta and Glatiramer Acetate

(2011) Murat Yildiz et al.   EUROPEAN NEUROLOGY

Quality of life, depression and fatigue in mildly disabled patients with relapsing–remitting multiple sclerosis receiving subcutaneous interferon beta-1a: 3-year results from the COGIMUS (COGnitive Impairment in MUltiple Sclerosis) study

(2011) F Patti et al.   Multiple Sclerosis Journal

Axonal damage in relapsing multiple sclerosis is markedly reduced by natalizumab

(2010) Martin Gunnarsson et al.   ANNALS OF NEUROLOGY

Reliability, practice effects, and change indices for Rao’s brief repeatable battery

(2010) Emilio Portaccio et al.   Multiple Sclerosis Journal

Natalizumab efficacy on cognitive impairment in MS

(2010) F. Mattioli et al.   NEUROLOGICAL SCIENCES

Natalizumab prevents the accumulation of cortical lesions in relapsing remitting multiple sclerosis: a preliminary report

(2010) F. Rinaldi et al.   NEUROLOGICAL SCIENCES

Swedish natalizumab (Tysabri) multiple sclerosis surveillance study

(2010) Fredrik Piehl et al.   NEUROLOGICAL SCIENCES

The effect of natalizumab on cognitive function in patients with relapsing-remitting multiple sclerosis: preliminary results of a 1-year follow-up study

(2010) Flavia Mattioli et al.   NEUROLOGICAL SCIENCES

Cognitive deficits in experimental autoimmune encephalomyelitis: neuroinflammation and synaptic degeneration

(2010) G. Mandolesi et al.   NEUROLOGICAL SCIENCES

Intellectual enrichment lessens the effect of brain atrophy on learning and memory in multiple sclerosis

(2010) J. F. Sumowski et al.   NEUROLOGY

Real-life impact of early interferonβ therapy in relapsing multiple sclerosis

(2009) M. Trojano et al.   ANNALS OF NEUROLOGY

Intellectual enrichment is linked to cerebral efficiency in multiple sclerosis: functional magnetic resonance imaging evidence for cognitive reserve

(2009) J. F. Sumowski et al.   BRAIN

The effects of natalizumab on inflammatory mediators in multiple sclerosis: prospects for treatment-sensitive biomarkers

(2009) M. Khademi et al.   EUROPEAN JOURNAL OF NEUROLOGY

Neuroprotection and neurogeneration in MS and its animal model EAE effected by glatiramer acetate

(2009) Ruth Arnon et al.   JOURNAL OF NEURAL TRANSMISSION

Inflammation Triggers Synaptic Alteration and Degeneration in Experimental Autoimmune Encephalomyelitis

(2009) D. Centonze et al.   JOURNAL OF NEUROSCIENCE

Cognitive reserve moderates the negative effect of brain atrophy on cognitive efficiency in multiple sclerosis

(2009) JAMES F. SUMOWSKI et al.   JOURNAL OF THE INTERNATIONAL NEUROPSYCHOLOGICAL SOCIETY

Multiple sclerosis associated fatigue during natalizumab treatment

(2009) Norman Putzki et al.   JOURNAL OF THE NEUROLOGICAL SCIENCES

Long-term effect of early treatment with interferon beta-1b after a first clinical event suggestive of multiple sclerosis: 5-year active treatment extension of the phase 3 BENEFIT trial

(2009) Ludwig Kappos et al.   LANCET NEUROLOGY

Longitudinal correlates of fatigue in multiple sclerosis

(2009) E Patrick et al.   Multiple Sclerosis Journal

Effects of immunomodulatory treatment with subcutaneous interferon beta-1a oncognitive decline in mildly disabled patients with relapsing—remitting multiple sclerosis

(2009) F. Patti et al.   Multiple Sclerosis Journal

Natalizumab treatment in multiple sclerosis: marked decline of chemokines and cytokines in cerebrospinal fluid

(2009) J. Mellergård et al.   Multiple Sclerosis Journal

Cognitive impairment in multiple sclerosis

(2008) Nancy D Chiaravalloti et al.   LANCET NEUROLOGY